Cannabis Dependence Clinical Trial
Official title:
Quitting Marijuana Use: Self-Report Study of Quitting Strategies and Withdrawal Symptoms
Verified date | May 3, 2012 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
- Marijuana is the most widely used illicit drug in the world, yet relatively little is known
about users who try to quit without formal treatment ( spontaneous quitting). Studies have
suggested that there are some common strategies that many individuals use in spontaneous
quitting, such as changing one s lifestyle or identity, reminding oneself of negative
consequences, support from family and friends, and religion. However, more research is needed
to determine potential treatment strategies for marijuana use.
Objectives:
- To identify strategies used to help with marijuana quitting among non-treatment seeking
adult marijuana users.
- To identify withdrawal symptoms experienced during marijuana quitting and their
relationship to the quitting strategies used and the outcome of the quit attempt.
- To evaluate whether subgroups of marijuana users differ in their experience of marijuana
quitting.
Eligibility:
- Individuals at least 18 years of age who have made at least one attempt to quit marijuana
use.
Design:
- The study will consist of one visit of approximately 1 to 2 hours.
- Participants will fill out three questionnaires. The questionnaires have different types
of questions, and will ask about background and lifestyle, marijuana use and craving
patterns and behaviors, and difficulties in previous attempts to quit using marijuana.
Status | Completed |
Enrollment | 822 |
Est. completion date | May 3, 2012 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
- INCLUSION CRITERIA: 1. age 18 or older 2. have made at least one attempt to quit marijuana use 3. able to give valid informed consent 4. ability to understand English |
Country | Name | City | State |
---|---|---|---|
United States | National Institute on Drug Abuse, Biomedical Research Center (BRC) | Baltimore | Maryland |
United States | Maryland Psychiatric Research Center (MPRC) 55 Wade Avenue | Catonsville | Maryland |
United States | Medical University of S. Carolina | Charleston | South Carolina |
Lead Sponsor | Collaborator |
---|---|
National Institute on Drug Abuse (NIDA) |
United States,
Adamson SJ, Sellman JD. A prototype screening instrument for cannabis use disorder: the Cannabis Use Disorders Identification Test (CUDIT) in an alcohol-dependent clinical sample. Drug Alcohol Rev. 2003 Sep;22(3):309-15. — View Citation
Boyd SJ, Tashkin DP, Huestis MA, Heishman SJ, Dermand JC, Simmons MS, Gorelick DA. Strategies for quitting among non-treatment-seeking marijuana smokers. Am J Addict. 2005 Jan-Feb;14(1):35-42. — View Citation
Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry. 2004 Nov;161(11):1967-77. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Marijuana Quit Questionnaire | 1 to 2 hours | ||
Secondary | Marijuana Craving Questionnaire, and Additional Questions about Marijuana Craving |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01005810 -
A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana
|
Phase 2 | |
Completed |
NCT00114439 -
Lithium Cannabis Withdrawal Study
|
Phase 2 | |
Completed |
NCT00350285 -
The Teen Marijuana Check-Up
|
Phase 2 | |
Completed |
NCT01618656 -
Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal
|
Phase 2 | |
Completed |
NCT01153490 -
Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine
|
Phase 4 | |
Completed |
NCT02946489 -
Facilitating the Behavioral Treatment of Cannabis Use Disorder
|
Phase 1 | |
Completed |
NCT02088177 -
Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT01565174 -
The Pharmaco-genetic and Brain Mechanisms Associated With Cannabis- Induced Psychosis
|
N/A | |
Completed |
NCT01697709 -
Quetiapine Pharmacotherapy for Cannabis Dependence
|
Phase 2 | |
Recruiting |
NCT04721353 -
Reducing Cannabis Overuse With Prazosin
|
Phase 4 | |
Completed |
NCT00167297 -
Atomoxetine for the Treatment of Cannabis Dependence
|
Phase 2 | |
Terminated |
NCT01598896 -
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
|
Phase 2/Phase 3 | |
Completed |
NCT01611948 -
Treatment for Cannabis Withdrawal and Dependence
|
Phase 2 | |
Recruiting |
NCT03221231 -
N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms
|
Phase 4 | |
Not yet recruiting |
NCT03366909 -
Mindfulness Meditation and Cannabis Dependence : Therapy Effectiveness
|
N/A | |
Completed |
NCT01639872 -
Clozapine for Cannabis Use in Schizophrenia
|
Phase 4 | |
Not yet recruiting |
NCT06334016 -
Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream
|
Early Phase 1 | |
Completed |
NCT01793961 -
Effects of Chronic Intake of Cannabis on Contrast Sensitivity
|
N/A | |
Completed |
NCT01834794 -
Targeting Tobacco Cessation During Treatment for Cannabis Use Disorders
|
N/A | |
Completed |
NCT01747850 -
Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence
|
Phase 2 |